Company Research Report: Omniscient Neurotechnology

Company Overview

Name

Omniscient Neurotechnology Pty Limited

Mission of the Company

Our mission is to improve the lives of billions through connectomics, because every brain can be better.

Founding Details

No information is available.

Key People

Dr. Michael Sughrue: Co-Founder, Director & Chief Medical Officer

A prominent neurosurgeon who built one of the largest neurosurgery practices in the US. He brings an unrivalled understanding of the brain to the business of building world-first brain insight products.

Dr. Stephane Doyen: Co-Founder, Director & Chief Data Scientist

Former head of Data Science - APR at Oliver Wyman, bringing extensive knowledge in machine learning and technical leadership.

Stephen Scheeler: CEO & Managing Director

Former head of Facebook ANZ, helped scale the business from a start-up stage to a US$700+ billion giant, bringing robust software business leadership to execute the company’s vision.

Headquarters

Suite L1.108, 477 Pitt Street, Haymarket NSW 2000, Australia

Number of Employees

No information is available.

Revenue

No information is available.

Company Expertise

Omniscient Neurotechnology is known for its innovative brain mapping technology, specifically through "connectomics," which involves detailed mapping and analysis of the brain’s structural and functional connections.

Products

Quicktome

Description:

Quicktome is an AI-powered connectomic analysis platform designed to provide clinicians with detailed insights into patient-specific brain networks and function.

Key Features:

Analyzes millions of data points from MRI and/or resting-state functional MRI (rs-fMRI) using AI-enabled post-processing.

Generates individualized brain maps to support prognosis and planning across various neurological conditions.

Informative for conditions ranging from surgeries, neuro-oncology to stroke recovery.

Recent Developments

New Products and Features

Quicktome has seen several feature enhancements enabling more efficient brain mapping and surgery planning.

Connectomic analysis revealed 7 new eloquent regions affecting surgical strategies for brain malformations.

Partnerships and Collaborations

Omniscient collaborates with top neuroscience institutions including University of Miami and Macquarie University Hospital.

Partnered with top MRI manufacturers to streamline brain mapping processes during routine MRI scans.

Awards and Recognition

Quicktome™: Won the 2022 South By Southwest® Innovation Award.

Omniscient Neurotechnology: Claimed the top prize at the SRS Shark Tank 2024.

Research Initiatives and Publications

Publications:

93 publications contributing to the field of connectomics.

301 citations highlighting academic impact.

37 patents issued by the USPTO.

Research Project: Human Connectome Project aimed at digitally mapping the structural and functional neural connections in the human brain.

Notable Studies:

"Connectomics as a prognostic tool of functional outcome in glioma surgery" (August 7, 2023)

"Connectomic insight into unique stroke patient recovery after rTMS treatment" (July 6, 2023)

Events

CNS Annual Meeting 2024: Participation in the Congress of Neurological Surgeons Annual Meeting scheduled for September 28 - October 2, 2024, in Washington D.C.

Conclusion

Omniscient Neurotechnology continues to be at the forefront of brain health innovation, leveraging advanced brain mapping technologies and strategic collaborations to enhance neurological care and therapy planning. Their groundbreaking work in connectomics is paving the way for more precise and effective treatments for various brain-related conditions.